The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Coronavirus is here to stay. The sooner we accept that ...
https://www.theguardian.com/.../sep/21/coronavirus-here-to-stay-moonshot
3 hours ago · Coronavirus is here to stay. The sooner we accept that, the better ... We would do better to abandon the fantasies of a quick-fix entirely. This is not a race, not even a marathon: there’s no .
Unless you have amazing hindsight capabilities, I doubt very much you would be able to sell at 4.40, at the high and buy back at the low!!
Wow , there certainly have been some games played with this share today .
I wish I had the balls to trade this one , sell at the 440p high then buy back in at 400p.
I bet it’s a lot more fun too !
I’d be too scared to do it though for fears of missing out on the big spike that I think all well researched holders know is coming this month .
with the £ millions ncyt coming in weekly / monthly m from Global sales to 130 countries
with the money ncyt has to spend on R & D , and test thar been released and to be released .
the number of new jobs that ncyt still recruiting for
the number of global distributers ,www.primerdesign.co.uk/about/distributors
Partnership with AZ, GSK & University of Cambridge
Will be watching for more news this week, be good if another step to help on way to achieving mid cap
https://www.sharebuyers.co.uk/shares/novacyt-shares-going-for-growth-poised-for-mid-cap-stardom/
The current COVID-19 pandemic has enabled Novacyt to demonstrate its unique ability to design and develop world-class clinical diagnostic products. Being one of the first to market with its PCR COVID-19 test has transformed the business from a very low market cap to a small cap with the potential to become an exciting mid-cap business. We also believe there is significant longevity in the demand for COVID-19 testing and this will mean Novacyt can continue to grow and drive significant cash flow.
This value creation will be used to deliver new growth in the rapidly expanding clinical diagnostics market. The pandemic has brought a global spotlight on the importance of diagnostic testing and we also believe this focus and interest will drive myriad new opportunities in the Diagnostics market. Novacyt is front and centre in supporting the world’s healthcare professionals during this challenging time and is in a strong position to build financial resources to maximise this long-term diagnostics opportunity.
VanV good to see you back posting again ,at ncyt ,people like myself Appreciated your research at ncyt ,and hoping you might find time to post more research at ncyt
this weeks, rns likely another step on way to mid cap ,
https://www.sharebuyers.co.uk/shares/novacyt-shares-going-for-growth-poised-for-mid-cap-stardom/
The current COVID-19 pandemic has enabled Novacyt to demonstrate its unique ability to design and develop world-class clinical diagnostic products. Being one of the first to market with its PCR COVID-19 test has transformed the business from a very low market cap to a small cap with the potential to become an exciting mid-cap business. We also believe there is significant longevity in the demand for COVID-19 testing and this will mean Novacyt can continue to grow and drive significant cash flow.
This value creation will be used to deliver new growth in the rapidly expanding clinical diagnostics market. The pandemic has brought a global spotlight on the importance of diagnostic testing and we also believe this focus and interest will drive myriad new opportunities in the Diagnostics market. Novacyt is front and centre in supporting the world’s healthcare professionals during this challenging time and is in a strong position to build financial resources to maximise this long-term diagnostics opportunity.
3 days and 3 rns , be good if this continues next week before AGM
Jgcw ,would think that many people who ncyt at 48p now thinking they regret not buying at that share price
Tougher Covid rules for millions in north-west England and ...
https://www.theguardian.com/world/2020/sep/18/stricter-covid...
3 hours ago · Tougher Covid rules for millions in north-west England and Yorkshire New measures include ban on mixing with other families and nightlife curfew from Tuesday.
could we see another of ncyt 4,15 rns ,for people to read over weekend ,think more likely to be next week before more rns might be seen
if this buying continues ,will mms go back to N T to buy again , if they running low with available shares
with the number of new products ncyt have
the growing number of Global distributors www.primerdesign.co.uk/about/distributors
how long until a mid cap company
https://walletinvestor.com/lse-stock-forecast/ncyt-stock-prediction#open
Https://www.sharebuyers.co.uk/shares/novacyt-shares-going-for-growth-poised-for-mid-cap-stardom/
The current COVID-19 pandemic has enabled Novacyt to demonstrate its unique ability to design and develop world-class clinical diagnostic products. Being one of the first to market with its PCR COVID-19 test has transformed the business from a very low market cap to a small cap with the potential to become an exciting mid-cap business. We also believe there is significant longevity in the demand for COVID-19 testing and this will mean Novacyt can continue to grow and drive significant cash flow.
This value creation will be used to deliver new growth in the rapidly expanding clinical diagnostics market. The pandemic has brought a global spotlight on the importance of diagnostic testing and we also believe this focus and interest will drive myriad new opportunities in the Diagnostics market. Novacyt is front and centre in supporting the world’s healthcare professionals during this challenging time and is in a strong position to build financial resources to maximise this long-term diagnostics opportunity.
D and d I agree when you posted the times article this morning I posted "no constraints" which on reflection was clear as mud. I'm all for a huge surge in price but some on twitter are now running with 16-16 pound by October!!!!! I'd take it but if broker note did say that I'd presume they would mean by.....(insert own selection and s****** like mutely (stop that pigeon)) it's the heat :)
Let’s break that £4 barrier today and start the new week with new high. Progression to Mid-cap is now inevitable. It’s only a matter of time.
https://www.thetimes.co.uk/article/novacyt-plans-deals-before-drop-in-covid-19-revenues-lgg5hmjhz
Is this the NUMIS effect!
https://www.wallstreet-online.de/nachricht/12939094-novacyt-s-a...
1 day ago · The Novacyt Group is an international diagnostics business generating an increasing portfolio
Or realise £21 much earlier if bought out! Happy with that outcome as well. Jam today!
MARKET REPORT: Novacyt sales up tenfold amid battle to ...
https://www.thisismoney.co.uk/money/markets/article-8744761
12 hours ago · MARKET REPORT: French Covid test maker Novacyt sales up tenfold since start of year amid battle to beat virus. By Francesca Washtell For The Daily Mail. Published: 16:54 EDT, 17
reposted this ,for previous post ,after looking at 5 year estimate ,if achieves ,any where near estimate price of £21 will be very pleased
https://walletinvestor.com/lse-stock-forecast/ncyt-stock-prediction#open
my plan is to hold some of these for 5 years ,when i look at estimate for 5 year investment if any where near estimate
will be happy with my investment ,if achieves £21 would be be very pleased
,how much news will ncyt ,release in next week before AGM .
also how much news before end of bonus month 17th October
with so much news due ,thinking plenty of rns to be seen
https://walletinvestor.com/lse-stock-forecast/ncyt-stock-prediction#open
The current COVID-19 pandemic has enabled Novacyt to demonstrate its unique ability to design and develop world-class clinical diagnostic products. Being one of the first to market with its PCR COVID-19 test has transformed the business from a very low market cap to a small cap with the potential to become an exciting mid-cap business. We also believe there is significant longevity in the demand for COVID-19 testing and this will mean Novacyt can continue to grow and drive significant cash flow.
This value creation will be used to deliver new growth in the rapidly expanding clinical diagnostics market. The pandemic has brought a global spotlight on the importance of diagnostic testing and we also believe this focus and interest will drive myriad new opportunities in the Diagnostics market. Novacyt is front and centre in supporting the world’s healthcare professionals during this challenging time and is in a strong position to build financial resources to maximise this long-term diagnostics opportunity.
Https://www.sharebuyers.co.uk/shares/novacyt-shares-going-for-growth-poised-for-mid-cap-stardom/
Https://www.sharebuyers.co.uk/shares/novacyt-shares-going-for-growth-poised-for-mid-cap-stardom/
A key challenge for any manufacturer supporting COVID-19 on a global basis has been the ability to expand and control its manufacturing capacity. We are immensely proud that we have scaled-up our manufacturing capacity by over 100 times in less than six months and can scale-up further as we add new products and as the market increases.
We now have significant levels of stock in order to respond to emergency customer demands and we are able to provide our customers the confidence in supply continuity. With the uncertainties of border controls, disrupted global transportation and uncertainties such as BREXIT we believe supply chain certainty is a key competitive advantage. Novacyt will continue to ensure that maintains its innovative, high performance position as the pandemic continues.